A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
Eli Lilly and Company
Ascentage Pharma Group Inc.
Newave Pharmaceutical Inc
Schrödinger, Inc.
AbbVie
Carna Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Accutar Biotechnology Inc
Institute of Hematology & Blood Diseases Hospital, China
Boryung Pharmaceutical Co., Ltd
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Stanford University
Emory University
Nurix Therapeutics, Inc.
Bio-Path Holdings, Inc.
Calibr, a division of Scripps Research
Nkarta, Inc.
Xencor, Inc.
Calibr, a division of Scripps Research
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Stanford University
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Stanford University
Dartmouth-Hitchcock Medical Center
Canadian Cancer Trials Group
Hutchmed
Brown University
AbbVie
Karyopharm Therapeutics Inc
Ohio State University Comprehensive Cancer Center
TG Therapeutics, Inc.
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
M.D. Anderson Cancer Center
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
University of Michigan Rogel Cancer Center
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Celgene
Alliance for Clinical Trials in Oncology
Ohio State University Comprehensive Cancer Center
Swiss Cancer Institute
Calithera Biosciences, Inc